Skip to Content
Merck
  • Prostate tumor growth is impaired by CtBP1 depletion in high-fat diet-fed mice.

Prostate tumor growth is impaired by CtBP1 depletion in high-fat diet-fed mice.

Clinical cancer research : an official journal of the American Association for Cancer Research (2014-05-21)
Cristian P Moiola, Paola De Luca, Florencia Zalazar, Javier Cotignola, Santiago A Rodríguez-Seguí, Kevin Gardner, Roberto Meiss, Pablo Vallecorsa, Omar Pignataro, Osvaldo Mazza, Elba S Vazquez, Adriana De Siervi
ABSTRACT

Clinical and epidemiologic data suggest that obesity is associated with more aggressive forms of prostate cancer, poor prognosis, and increased mortality. C-terminal-binding protein 1 (CtBP1) is a transcription repressor of tumor suppressor genes and is activated by NADH binding. High calorie intake decreases intracellular NAD(+)/NADH ratio. The aim of this work was to assess the effect of high-fat diet (HFD) and CtBP1 expression modulation over prostate xenograft growth. We developed a metabolic syndrome-like disease in vivo model by feeding male nude mice with HFD during 16 weeks. Control diet (CD)-fed animals were maintained at the same conditions. Mice were inoculated with PC3 cells stable transfected with shCtBP1 or control plasmids. Genome-wide expression profiles and Gene Set Enrichment Analysis (GSEA) were performed from PC3.shCtBP1 versus PC3.pGIPZ HFD-fed mice tumors. No significant differences were observed in tumor growth on CD-fed mice; however, we found that only 60% of HFD-fed mice inoculated with CtBP1-depleted cells developed a tumor. Moreover these tumors were significantly smaller than those generated by PC3.pGIPZ control xenografts. We found 823 genes differentially expressed in shCtBP1 tumors from HFD-fed mice. GSEA from expression dataset showed that most of these genes correspond to cell adhesion, metabolic process, and cell cycle. Metabolic syndrome-like diseases and CtBP1 expression cooperate to induce prostate tumor growth. Hence, targeting of CtBP1 expression might be considered for prostate cancer management and therapy in the subset of patients with metabolic syndromes.

MATERIALS
Product Number
Brand
Product Description

Letrozole, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Letrozole, ≥98% (HPLC)
Supelco
Letrozole, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Hematoxylin
Sigma-Aldrich
Hematoxylin, certified by the Biological Stain Commission